ZipBio announced an exclusive license agreement with MeiraGTx Holdings. Under the agreement, MeiraGTx will receive exclusive rights to ZipBio's first-in-class therapies for geographic atrophy, targeting the complement pathway, ZipBio said in a press release. 

According to the press release, the licensing deal combines MeiraGTx's leadership in vector design, clinical development, and in-house manufacturing of genetic medicines, and ZipBio's expertise in de novo-designed protein therapeutics, developed using its Compact generative artificial intelligence (AI) platform. Compact is ZipBio's proprietary generative AI platform for designing protein therapeutics. It enables the creation of Zip drugs—compact, multifunctional, and logic-gated proteins, the company said. RP